Bio/Pharmaceutical Analysis Techniques

Laboratory Equipment and Instruments

Analytics

Data and Artificial Intelligence

Inhalation Drugs

Parenterals and Injectables

Solid/Semi-Solid Dosage

Specialty Dosage Drugs

Dosage Forms

APIs and Excipients

Formulation and Drug Delivery

Ingredients

Intellectual Property and Patents

Process and Scaling

Drug Development

Aseptic/Sterile Processing

Equipment

Manufacturing, Biologic Drugs

Manufacturing, Biosimilars and Biobetters

Manufacturing, Cell Therapies

Manufacturing, Gene Therapies

Manufacturing, Inhalation Drugs

Manufacturing, Parenterals and Injectables

Manufacturing, Solid and Semi-Solid Dosage Drugs

Packaging and Distribution

Process and Automation

Supply Chain

Manufacturing

Contract Analytical Services

Contract Development Services

Contract Manufacturing Services

Contract Research Services

Logistics and Distribution

Regulatory Consulting

Outsourcing

Ask the Expert

Quality Assurance/Quality Control

Regulatory Oversight and Compliance

Quality Systems

News

Business

Bio/Pharma Business

All News

Bio/Pharma News

Publications

All Publications

PharmTech

PharmTech Europe

Resources

Marketplace

ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management

Peer-Reviewed Research

PharmTech Products

Pharma Insights

Whitepapers

Webcasts

Multimedia

All Videos

Behind The Headlines

Buy, Sell, Hold

Drug Digest Videos

Drug Solutions Podcast

Peer Exchange

Sexy Science

Tech Talk

Conference

Conference Coverage

Conference Listing

Events

Subscribe

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

About Us

Advertise

Contact Us

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Technology - Pharma News and Development Insights

Twitter

LinkedIn

Spotlight

Topic

COVID-19 Update

APIs

Analytical Method Development

Aseptic Processing

Biologic Drugs

Drug Delivery

Excipients

Formulation

Packaging

Process Control/PAT

Process Development

QA/QC

Regulatory Action

1rem

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

EMA Approves Lower GWP Alternative for Inhalation Medicine

Kloxxado was approved by FDA in 2021 for emergency treatment of opioid overdose, and Emergent also distributes the FDA-approved over-the-counter treatment Narcan.

Hikma and Emergent Enter Six-Year Partnership to Sell Naloxone Spray in US and Canada

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

Bespak and Orbia Fluor & Energy Materials Collaborate on Climate-Friendly Inhalers

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.

Phillips Medisize to Acquire Vectura, Expanding Inhalation Drug Delivery Capabilities

In an interview with Pharmaceutical Technology®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.

International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma

While the pharmaceutical industry has made strides towards diversity, equity, and inclusion, there is still room for improvement, asserts Sheryl Johnson, pharma application development manager at Orbia Fluor & Energy Materials. Many companies, such as Orbia, are taking proactive approaches to help improve gender diverse representations within their workforces. Ongoing commitment from all areas across the industry is required to achieve full diversity, she explains.

“Women in particular, can bring unique perspectives, talents, [and] approaches that can drive innovation, particularly in the pharma industry,” Johnson adds. “For instance, female leaders can often excel in collaborative and inclusive leadership styles, which I feel can help foster creativity and new ideas. I find women are very open to sharing of new ideas and provide supportive attitude to research management and development through considered and empathetic communication.”

Looking at sustainability challenges in particular and drawing on her experiences within the inhaled drug space, Johnson points to the groundbreaking research and leadership being performed by women helping to drive greater sustainable practices, “people like Sara Panigone from Chiesi, who's leading initiatives in developing carbon minimum inhalers and has been prominent voice in sustainability and in within the industry, and Maureen Hardwick from the International Pharmaceutical Aerosol Consortium, [who’s] been a key figure in advancing environmental policies and sustainable efforts,” she says.

“I think the future of gender diversity in the pharma industry looks promising with more women taking on leadership roles and contributing to decision making processes,” Johnson summarizes. “I think the shift will likely lead to a more inclusive, innovative approach to healthcare for inhalers and inhaled drugs, we can probably expect continued advancements in technology, in formulation and making treatments more effective, more environmentally friendly, and I think the industry is poised to make significant strides in both areas benefitting both patients and the world alike.”

Sheryl Johnson is Pharma Application Development Manager at Orbia Fluor & Energy Materials. Sheryl is a highly respected authority in the pharmaceutical aerosol industry with almost two decades' worth of experience in medical chemical development and research. She is on the board at the International Pharmaceutical Aerosol Consortium on Regulation & Science(IPAC RS), frequently contributed to the publishing of papers through working groups, and actively participates at industry organised conference events such as Respiratory Drug Delivery. After earning her Master's in Organic Chemistry from the University of Hull, she worked as a senior development chemist at Contract Chemicals, where she discovered her love for laboratory work. Her subsequent role at Orbia provided experience in process development, hazardous materials handling and formulation chemistry. Now, with over 13 years at Orbia Fluor & Energy Materials, she serves as Pharma Application Development Manager, overseeing the safe production and development of Zephex 152a MDIs.


Videos

PharmTech News

Business News

Vivek Gupta, PhD, St. John’s University, discusses the formulation of inhalation drugs.

Developing Inhalation Drugs

The respiratory system is a complex organ that has specific implications to consider when developing drugs that are delivered through inhalation, according to Vivek Gupta, PhD, associate dean for Graduate Education and Research, associate professor, Pharmaceutical Sciences, St. John’s University, Queens, New York. One of the formulation considerations is the choice of excipients.

“When we talk about what kind of excipients can be used, and what impacts the choice of excipients, I think the primary thing that comes into mind is safety of those excipients. Because it's one thing for an excipient to be given orally, where it goes into the intestinal tract, gets delicate while it is traveling to the intestinal tract, and eventually into the bloodstream. Instead of that, when anything is given administered into the lungs, they tend to accumulate. They may or may not get metabolized, depending on what kind of environment, [the] kind of enzymes [needed] for metabolism, and they safety challenges [these excipients] pose. [Most] of the excipients that are used for inhaled dosage forms are more or less the same that have been approved for other routes of administrations as well. However, the quality of those excipients could be different.”

Click on the above video for a discussion with Dr. Gupta about the challenges of formulating inhalation drug products. Dr. Gupta will be providing an on-demand prologue discussion, 

Advances and Challenges in Inhaled Drug Product Development,

 for AAPS PharmSci 360 in 2024. AAPS PharmSci 360 is being held from October 20–23, 2024 in Salt Lake City, UT.

For a preview of what's to come at the AAPS PharmSci 360 show in October, Pharmaceutical Technology® spoke with Vivek Gupta, PhD, associate dean for Graduate Education and Research, associate professor, Pharmaceutical Sciences, St. John’s University, Queens, New York, about the formulation of inhalation dosage forms.

Latest Conference

AAPS PharmSci 360 2024: Developing Inhalation Drugs

Inhalation Drugs

Latest News